{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:22:56Z","timestamp":1788870176140,"version":"build-2803163510"},"reference-count":88,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.neuropharm.2011.02.020","type":"journal-article","created":{"date-parts":[[2011,3,7]],"date-time":"2011-03-07T15:37:16Z","timestamp":1299512236000},"page":"1252-1262","source":"Crossref","is-referenced-by-count":74,"title":["Synergistic interactions between PDE4B and GSK-3: DISC1 mutant mice"],"prefix":"10.1016","volume":"62","author":[{"given":"Tatiana V.","family":"Lipina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Roder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2011.02.020_bib1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ceb.2005.01.003","article-title":"Arrestin times for compartmentalised cAMP signalling and phosphodiesterase-4 enzymes","volume":"17","author":"Baillie","year":"2005","journal-title":"Curr. Opin. Cell. Biol."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib2","doi-asserted-by":"crossref","first-page":"15020","DOI":"10.1073\/pnas.95.25.15020","article-title":"Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-term potentiation and improves memory","volume":"95","author":"Barad","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib3","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1073\/pnas.0307921101","article-title":"Lithium antagonizes dopamine-dependent behaviors mediated by an AKT\/glycogen synthase kinase 3 signaling cascade","volume":"101","author":"Beaulieu","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib4","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1073\/pnas.0711496105","article-title":"Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency","volume":"105","author":"Beaulieu","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1146\/annurev.pharmtox.011008.145634","article-title":"Akt\/GSK-3 signaling in the action of psychotropic drugs","volume":"49","author":"Beaulieu","year":"2009","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev.physiol.70.113006.100455","article-title":"Calcium cycling and signaling in cardiac myocytes","volume":"70","author":"Bers","year":"2008","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1742-2094-6-9","article-title":"Lipopolysaccharide-induced interleukin-6\u00a0p.oduction is controlled by glycogen synthase kinase-3 and STAT3 in the brain","volume":"6","author":"Beurel","year":"2009","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib8","doi-asserted-by":"crossref","first-page":"S252","DOI":"10.1038\/sj.bjp.0706495","article-title":"Phosphodiesterase inhibitors","volume":"147","author":"Boswell-Smith","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1001\/archpsyc.1990.01810140081011","article-title":"Sensorimotor gating and schizophrenia. Human and animal model studies","volume":"47","author":"Braff","year":"1990","journal-title":"Arch. Gen. Psychiatry."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib10","first-page":"294","article-title":"Gating and habituation deficits in the schizophrenia disorders","volume":"11","author":"Braff","year":"1995","journal-title":"Clinic. Neurosci."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib11","doi-asserted-by":"crossref","first-page":"12768","DOI":"10.1523\/JNEUROSCI.3355-09.2009","article-title":"Understanding the role of DISC1 in psychiatric disease and during normal development","volume":"29","author":"Brandon","year":"2009","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib90","doi-asserted-by":"crossref","first-page":"7957","DOI":"10.1074\/jbc.M109.091603","article-title":"A noncatalytic domain of glycogen synthase kinase-3 (GSK-3) is essential for activity","volume":"285","author":"Buescher","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib12","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nbt.1598","article-title":"Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety","volume":"28","author":"Burgin","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1471-4159.2010.06581.x","article-title":"The neuron-specific isoform of glycogen synthase kinase-3beta is required for axon growth","volume":"113","author":"Casta\u00f1o","year":"2010","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/sj.mp.4002106","article-title":"The DISC1 locus in psychiatric illness","volume":"13","author":"Chubb","year":"2008","journal-title":"Mol. Psychiatry."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib15","article-title":"Behavioral phenotyping of v-akt murine thymoma viral oncogene homolog 1-deficient mice reveals a sex-specific prepulse inhibition deficit in females that can be partially alleviated by glycogen synthase kinase-3 inhibitors but not by antipsychotics","author":"Chen","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.neuron.2007.04.015","article-title":"Behavioral phenotypes of disc1 missense mutations in mice","volume":"54","author":"Clapcote","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib18","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0165-6147(02)02017-5","article-title":"Assessing antidepressant activity in rodents: recent developments and future needs","volume":"23","author":"Cryan","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib19","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1037\/0735-7044.119.2.595","article-title":"Rolipram attenuates MK-801-induced deficits in latent inhibition","volume":"119","author":"Davis","year":"2005","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib20","doi-asserted-by":"crossref","first-page":"e9807","DOI":"10.1371\/journal.pone.0009807","article-title":"A\u00a0new alpha5beta1 integrin-dependent survival pathway through GSK-3 beta activation in leukemic cells","volume":"5","author":"De Toni-Costes","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/ng1296","article-title":"Convergent evidence for impaired AKT1-GSK3\u03b2 signaling in schizophrenia","volume":"36","author":"Emamian","year":"2004","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib22","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.1523\/JNEUROSCI.0604-06.2006","article-title":"Full reversal of Alzheimer\u2019s disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3","volume":"26","author":"Engel","year":"2006","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib23","doi-asserted-by":"crossref","first-page":"11960","DOI":"10.1073\/pnas.220413597","article-title":"Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A","volume":"97","author":"Fang","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib24","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.schres.2008.01.029","article-title":"PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia","volume":"101","author":"Fatemi","year":"2008","journal-title":"Schizophr Res."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib25","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1176\/appi.ajp.2009.08121873","article-title":"Roles of the Akt\/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action","volume":"167","author":"Freyberg","year":"2010","journal-title":"Am. J. Psychiatry."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib89","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.pnpbp.2003.09.003","article-title":"Animal behavior models of the mechanisms underlying antipsychotic atypicality","volume":"27","author":"Geyer","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002130100811","article-title":"Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review","volume":"156","author":"Geyer","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib27","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.mp.4001518","article-title":"Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers","volume":"9","author":"Gould","year":"2004","journal-title":"Mol. Psychiatry."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib28","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1017\/S1461145704004535","article-title":"AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test","volume":"7","author":"Gould","year":"2004","journal-title":"Int. J. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib29","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/sj.npp.1300731","article-title":"Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs","volume":"30","author":"Gould","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib30","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0091-3057(91)90186-6","article-title":"Behavioral effects of rolipram and structurally related compounds in mice: behavioral sedation of cAMP phosphodiesterase inhibitors","author":"Griebel","year":"1991","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/sj.mp.4001558","article-title":"Schizophrenia genes, gene expression, and\u00a0neuropathology: on the matter of their convergence","volume":"10","author":"Harrison","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib32","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.biopsych.2005.01.040","article-title":"Impaired prepulse inhibition of acoustic startle in obsessive-compulsive disorder","volume":"57","author":"Hoeng","year":"2005","journal-title":"Biol. Psych."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1037\/h0022325","article-title":"Acoustic variables in the modification of startle reaction in the rat","volume":"60","author":"Hoffman","year":"1965","journal-title":"J.\u00a0Comp. Physiol. Psychol."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib34","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S1359-6446(05)03622-6","article-title":"Keynote review: phosphodiesterase-4 as a therapeutic target","volume":"10","author":"Houslay","year":"2005","journal-title":"Drug Discov. Today."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj20021698","article-title":"PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization","volume":"370","author":"Houslay","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib36","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.2174\/1389450110607011389","article-title":"Multiple roles for glycogen synthase kinase-3 as a drug target in Alzheimer\u2019s disease","volume":"7","author":"Huang","year":"2006","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib37","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.tins.2009.05.007","article-title":"Neurodevelopmental mechanisms of schizophrenia: understanding disturbed postnatal brain maturation through neuregulin-1-ErbB4 and DISC1","volume":"32","author":"Jaaro-Peled","year":"2009","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib38","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/schbul\/sbp133","article-title":"Review of pathological hallmarks of schizophrenia: comparison of genetic models with patients and nongenetic models","volume":"36","author":"Jaaro-Peled","year":"2010","journal-title":"Schizophr Bull."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1389450110607011421","article-title":"Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions","volume":"7","author":"Jope","year":"2006","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib40","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.biopsych.2004.01.008","article-title":"Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus","volume":"55","author":"Kaidanovich-Beilin","year":"2004","journal-title":"Biol. Psychiatry."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib41","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1756-6606-2-35","article-title":"Abnormalities in brain structure and behavior in GSK-3 mutant mice","volume":"2","author":"Kaidanovich-Beilin","year":"2009","journal-title":"Mol. Brain"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib42","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0952-3278(92)90059-R","article-title":"Effect of haloperidol on cyclic AMP and inositol trisphosphate in rat striatum in vivo","volume":"46","author":"Kaneko","year":"1992","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib43","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.neuroscience.2006.09.026","article-title":"Rolipram: a specific phosphodiestirase 4 inhibitor with potential antipsychotic activity","volume":"144","author":"Kanes","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib44","doi-asserted-by":"crossref","first-page":"8830","DOI":"10.1523\/JNEUROSCI.1292-10.2010","article-title":"Protein phosphatase 2a and glycogen synthase kinase 3 signaling modulate prepulse inhibition of the acoustic startle response by altering cortical M-Type potassium channel activity","volume":"30","author":"Kapfhamer","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib45","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1001\/archgenpsychiatry.2010.10","article-title":"Increased synaptic dopamine function in associate regions of the striatum in schizophrenia","volume":"67","author":"Kegeles","year":"2010","journal-title":"Arch. Gen. Psychiatry."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib46","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/sj.npp.1301099","article-title":"Constitutive activation of Galphas within forebrain neurons causes deficits in sensorimotor gating because of PKA-dependent decreases in cAMP","volume":"32","author":"Kelly","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib47","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.neuron.2009.08.008","article-title":"Disc1 regulates new neuron development in the adult brain via modulation of Akt-mTOR signaling through KIAA1212","volume":"63","author":"Kim","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib48","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2174\/1389450110607011377","article-title":"Glycogen synthase kinase-3 \u2013 an overview of an over-achieving protein kinase","volume":"7","author":"Kockeritz","year":"2006","journal-title":"Curr. Drug Target."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib49","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1358\/dnp.2007.20.7.1149632","article-title":"The role of glycogen synthase kinase-3beta in schizophrenia","volume":"20","author":"Koros","year":"2007","journal-title":"Drug News Perspect."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib50","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1016\/j.bmc.2009.03.061","article-title":"Identification of PDE4B Over 4D subtype-selective inhibitors revealing an unprecedented binding mode","volume":"17","author":"Kranz","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib52","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1017\/S1461145706006547","article-title":"Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics","volume":"10","author":"Li","year":"2007","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib53","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00213-005-2210-x","article-title":"Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia","volume":"179","author":"Lipina","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib54","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00213-009-1749-3","article-title":"A\u00a0new model of the disrupted latent inhibition on C57BL\/6J mice","volume":"208","author":"Lipina","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib55","article-title":"Genetic and pharmacological evidence for schizophrenia-related disc1 interaction with GSK-3","author":"Lipina","year":"2010","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib56","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4088\/JCP.v65n0206","article-title":"Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials","volume":"65","author":"Leucht","year":"2004","journal-title":"J.\u00a0Clin. Psychiatry."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib57","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.tins.2007.02.002","article-title":"Schizophrenia as a GSK-3 dysregulation disorder","volume":"30","author":"Lovestone","year":"2007","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib58","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1046\/j.1471-4159.2002.00939.x","article-title":"BDNF-mediated signal transduction is modulated by GSK-3 beta and mood stabilizing agents","volume":"82","author":"Mai","year":"2002","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib59","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.cell.2008.12.044","article-title":"Disrupted in Schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3b\/b-Catenin Signaling","volume":"136","author":"Mao","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib60","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.neuroscience.2004.07.038","article-title":"Phosphodiesterase inhibitors: a novel mechanisms for receptor-independent antipsychotic medications","volume":"129","author":"Maxwell","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib61","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/brain\/awf150","article-title":"Brain anatomy and sensorimotor gating in Asperger\u2019s syndrome","volume":"125","author":"McAlonan","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib62","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/hmg\/9.9.1415","article-title":"Disruption of two novel genes by a translocation co-segregating with schizophrenia","volume":"9","author":"Millar","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib91","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1126\/science.1112915","article-title":"DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling","volume":"310","author":"Millar","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib63","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0014-5793(97)00688-1","article-title":"Lithium inhibits Alzheimer\u2019s disease-like tau protein phosphorylation in neurons","volume":"411","author":"Mu\u00f1oz-Monta\u00f1o","year":"1997","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib64","doi-asserted-by":"crossref","first-page":"9513","DOI":"10.1523\/JNEUROSCI.1493-07.2007","article-title":"Isoform-selective susceptibility of DISC1\/phosphodiesterase-4 complexes to dissociate by elevated intracellular cAMP levels","volume":"27","author":"Murdoch","year":"2007","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib65","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/BF02704114","article-title":"Cyclic AMP response element binding protein and brain-derived neurotrophic factor: molecules that modulate our mood?","volume":"31","author":"Nair","year":"2006","journal-title":"J.\u00a0Biosci."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib66","doi-asserted-by":"crossref","first-page":"8786","DOI":"10.1073\/pnas.0402595101","article-title":"The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery","volume":"101","author":"Nikulina","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib67","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/nn.2647","article-title":"Animal models of neuropsychiatric disorders","volume":"13","author":"Nestler","year":"2010","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib68","article-title":"Evidence of statistical epistasis between DISC1, CIT and NDEL1 impacting risk for schizophrenia: biological validation with functional neuroimaging","author":"Nicodemus","year":"2010","journal-title":"Hum Genet"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib69","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jpsychires.2008.01.013","article-title":"Positive association of the PDE4B (phosphodiesterase 4B) gene with schizophrenia in the Japanese population","volume":"43","author":"Numata","year":"2008","journal-title":"J.\u00a0Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib70","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1073\/pnas.0500466102","article-title":"Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo","volume":"102","author":"Noble","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib71","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.tips.2004.01.003","article-title":"Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4)","volume":"25","author":"O\u2019Donnell","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib72","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s002130050333","article-title":"Inbred strain differences in prepulse inhibition of the mouse startle response","volume":"132","author":"Paylor","year":"1997","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib73","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.neuron.2007.01.029","article-title":"LTP inhibits LTD in the hippocampus via regulation of GSK3beta","volume":"53","author":"Peineau","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib74","doi-asserted-by":"crossref","first-page":"e8911","DOI":"10.1371\/journal.pone.0008911","article-title":"Light and electron microscopy study of glycogen synthase kinase-3 beta in the mouse brain","volume":"27","author":"Perez-Costas","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib75","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1176\/ajp.151.3.363","article-title":"Information-processing deficits and thought disorder in schizophrenia","volume":"151","author":"Perry","year":"1994","journal-title":"Am. J. Psychiatry."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib76","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.biopsych.2005.09.025","article-title":"Sensrimotor gating deficit in adults with autism","volume":"61","author":"Perry","year":"2007","journal-title":"Biol. Psychiatry."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib77","first-page":"R44","article-title":"Antipsychotic activity of rolipram in schizophrenia patients: pilot study","volume":"308","author":"Pietzcker","year":"1979","journal-title":"Naunyn. Schmiedebers. Arch. Pharmacol."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib78","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/YPG.0b013e328014492b","article-title":"The PDE4B gene confers sex-specific protection against schizophrenia","volume":"17","author":"Pickard","year":"2007","journal-title":"Psychiatr. Genet."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib79","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.bbr.2009.04.021","article-title":"Prepulse inhibition and genetic mouse models of schizophrenia","volume":"204","author":"Powell","year":"2009","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib80","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.pnpbp.2008.05.020","article-title":"Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice","volume":"32","author":"Rosa","year":"2008","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib81","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/414799a","article-title":"Insulin signalling and the regulation of glucose and lipid metabolism","volume":"414","author":"Saltiel","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib82","first-page":"43","article-title":"Effect of rolipram, a phosphodiesterase inhibitor and potential antidepressant, on the firing rate of central monoaminergic neurons in the rat","volume":"288","author":"Scuv\u00e9e-Moreau","year":"1987","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib84","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00213-007-0727-x","article-title":"Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme","volume":"192","author":"Siuciak","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib85","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1126\/science.1089681","article-title":"Diverse psychotomimetics act through a common signaling pathway","volume":"302","author":"Svenningsson","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib86","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.biopsych.2009.01.014","article-title":"Association between genes of disrupted in schizophrenia 1 (DISC1) interactors and schizophrenia supports the role of the DISC1\u00a0p.thway in the etiology of major mental illnesses","volume":"65","author":"Tomppo","year":"2009","journal-title":"Biol. Psychiatry."},{"key":"10.1016\/j.neuropharm.2011.02.020_bib87","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/sj.npp.1300440","article-title":"Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into CA1 subregion of the rat hippocampus","volume":"29","author":"Zhang","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2011.02.020_bib88","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00213-006-0369-4","article-title":"Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats","volume":"186","author":"Zhang","year":"2006","journal-title":"Psychopharmacology (Berl)"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390811000906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390811000906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T23:50:25Z","timestamp":1560037825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390811000906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":88,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0028390811000906"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2011.02.020","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}